Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Fate Therapeutics Inc
FATE | US
2.57
USD-0.17
-6.20%
FATE | US
About Fate Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
2.57
Open
2.71
High
2.77
Low
2.55
Fate Therapeutics Inc. a clinical-stage biopharmaceutical company develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522 to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego California.
View LessFATE | US
Risk
164.2
Sharpe
1.11
Luna's Score
54/100
Recommendation
Hold
Luna says (FATE | US)
What's Working
Positive Momentum
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
120.5%1 month
164.2%3 months
116.8%6 months
98.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.93
Debt to equity
0.25
Debt to assets
0.19
Ent. to EBITDA
-2.59
Ent. to rev.
13.28
PEG
-
Other Fundamentals
EBITDA
-163.44M
MarketCap
292.67M
MarketCap(USD)
292.67M
Div. yield
-
Op. margin
-665.73
Erngs. growth
-
Rev. growth
625.80
Ret. on equity
-42.10
Short ratio
13.95
Short perc.
14.29
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.29
Range1M
1.35
Range3M
1.84
Volumes: Market Activity
Rel. volume
0.58
Price X volume
7.51M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.59 | - | Cheaper |
| Ent. to Revenue | 13.28 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.93 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 116.76 | - | Riskier |
| Debt to Equity | 0.25 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 292.67M | - | Emerging |
